Fluconazole-, Amphotericin-B-, Caspofungin-, and Anidulafungin-Resistant Candida ciferrii: An Unknown Cause of Systemic Mycosis in a Child

[1]  J. Sobel,et al.  Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. , 2009, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[2]  T. Tan,et al.  A retrospective analysis of antifungal susceptibilities of Candida bloodstream isolates from Singapore hospitals. , 2008, Annals of the Academy of Medicine, Singapore.

[3]  D. Perlin.  Resistance to echinocandin-class antifungal drugs. , 2007, Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy.

[4]  H. Hof,et al.  In vitro susceptibility of Candida species to five antifungal agents in a German university hospital assessed by the reference broth microdilution method and Etest. , 2007, The Journal of antimicrobial chemotherapy.

[5]  L. Polonelli,et al.  Voriconazole activity against clinical yeast isolates: a multicentre Italian study. , 2005, International journal of antimicrobial agents.

[6]  J. Bouchara,et al.  Prevalence ofCandida ciferrii in elderly patients with trophic disorders of the legs , 1995, Mycopathologia.

[7]  N. K. Rij.  Candida ciferrii, a new yeast species , 1965, Mycopathologia et mycologia applicata.

[8]  M. Pfaller,et al.  Geographic Variation in the Susceptibilities of Invasive Isolates of Candida glabrata to Seven Systemically Active Antifungal Agents: a Global Assessment from the ARTEMIS Antifungal Surveillance Program Conducted in 2001 and 2002 , 2004, Journal of Clinical Microbiology.

[9]  S. Ichiyama,et al.  National surveillance of species distribution in blood isolates of Candida species in Japan and their susceptibility to six antifungal agents including voriconazole and micafungin. , 2004, The Journal of antimicrobial chemotherapy.

[10]  Yun-Liang Yang,et al.  Distribution and antifungal susceptibility of Candida species causing candidemia from 1996 to 1999. , 2003, Diagnostic microbiology and infectious disease.

[11]  M. Pfaller,et al.  Twelve years of fluconazole in clinical practice: global trends in species distribution and fluconazole susceptibility of bloodstream isolates of Candida. , 2004, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[12]  L. R. Ásmundsdóttir,et al.  Increasing Incidence of Candidemia: Results from a 20-Year Nationwide Study in Iceland , 2002, Journal of Clinical Microbiology.

[13]  R N Jones,et al.  National surveillance of nosocomial blood stream infection due to Candida albicans: frequency of occurrence and antifungal susceptibility in the SCOPE Program. , 1998, Diagnostic microbiology and infectious disease.

[14]  D. Ahearn,et al.  Candida ciferrii and Candida chiropterorum isolated from clinical specimens , 1983, Journal of clinical microbiology.